Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPETE: 177Lu-edotreotide PRRT vs Everolimus in Progressive SSTR-positive GEP-NET
2023-510444-21-00Phase 3Authorised
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Jun 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177-edotreotide in gastrointestinal neuroendocrine tumor and Pancreatic neuroendocrine tumor (pNET) (2 arms), sponsored by ITM Isotope Technologies Munich. Primary endpoint: Progression-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
gastrointestinal neuroendocrine tumorPancreatic neuroendocrine tumor (pNET)
Beyond the preview
Go deeper on 2023-510444-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510444-21-00.